Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents

Table 1

Characteristics of MS patient candidates for AHSCT.

Characteristics of MS patient candidates of AHSCT	Level of evidence [19]
Relapsing-remitting MS [84]	B-R
2 or more clinical relapses or 1 relapse and MRI gadolinium-enhancing lesion(s) at a separate time within the previous 12 months despite receiving treatment with DMT [84]	B-R
EDSS 2.0-6.0 [84]	B-R
Younger patients with shorter disease duration [85, 86]	B-NR
Malignant (Marburg type) MS and severe disability [85]	B-NR
No comorbidities [20, 85]	B-NR
Able to ambulate independently [3]	B-NR

AHSCT: autologous hematopoietic stem cell transplantation; MS: multiple sclerosis; DMT: disease-modifying therapies; EDSS: Expanded Disability Status Scale; B-R (randomized): moderate-quality evidence from 1 or more randomized clinical trials; B-NR (nonrandomized): moderate-quality evidence from 1 or more well-designed, well-executed nonrandomized studies, observational studies, or registry studies.